The history of Sildenafil presents a complex picture for shareholders. While the initial introduction generated massive returns, the lapse of its exclusive rights opened the door to off-brand alternatives, dramatically eroding sales. This creates a unique risk for pharmaceutical companies relying on comparable blockbuster offerings, suggesting that

The story of Viagra, and its parent company copyright, presents a complex case study for investors. Initially a blockbuster drug, yielding billions in revenue , its exclusivity period created a wave of lower-priced alternatives , significantly diminishing its market share . While some businesses may seek to capitalize on related treatments , the pr